经皮经肝透视引导下治疗胆总管结石的有效性和并发症率:一项单臂Meta分析
该单臂Meta分析纳入2010年1月至2022年6月发表的18项研究共2554例患者,评估经皮经肝透视引导下治疗(PTFM)胆总管结石的成功率和并发症率。汇总结果显示,PTFM总体结石清除率为97.1%(95%CI 95.7-98.5%),首次尝试清除率为80.5%(95%CI 72.3-88.6%),总体并发症率为13.8%(95%CI 9.7-18.0%),主要并发症率为2.8%(95%CI 1.4-4.2%),次要并发症率为9.3%(95%CI 5.7-12.8%)。经胆囊途径治疗的总体结石清除率为88.5%(95%CI 81.2-95.7%),并发症率为23.0%(95%CI 5.7-40.4%)。作者认为,在内镜治疗失败或不可行的情况下可考虑经皮管理。
要点
- PTFM治疗胆总管结石的汇总总体结石清除率为97.1%(95%CI 95.7-98.5%)。
- PTFM的汇总总体并发症率为13.8%(95%CI 9.7-18.0%),主要并发症率为2.8%(95%CI 1.4-4.2%)。
- 经胆囊途径的汇总总体结石清除率为88.5%,并发症率为23.0%。
核心结论
- PTFM治疗胆总管结石的汇总总体结石清除率为97.1%,首次尝试清除率为80.5%,总体并发症率为13.8%,主要并发症率为2.8%;经胆囊途径的总体结石清除率为88.5%,并发症率为23.0%。
研究设计与样本
- 系统综述与Meta分析,检索多个数据库,纳入2010年1月至2022年6月发表的18项研究共2554例患者,采用随机效应模型汇总成功率和并发症率及95%CI。
诊断标准与关键数值
- PTFM治疗胆总管结石的汇总总体结石清除率为97.1%(95%CI 95.7-98.5%)。
- PTFM首次尝试结石清除率为80.5%(95%CI 72.3-88.6%)。
- PTFM汇总总体并发症率为13.8%(95%CI 9.7-18.0%),主要并发症率为2.8%(95%CI 1.4-4.2%),次要并发症率为9.3%(95%CI 5.7-12.8%)。
- 经胆囊途径治疗胆总管结石的汇总总体结石清除率为88.5%(95%CI 81.2-95.7%),并发症率为23.0%(95%CI 5.7-40.4%)。
临床应用与阅片要点
- 内镜治疗失败或不可行是PTFM最常见的适应证。
- 作者认为,在内镜治疗失败或不可行的情况下可考虑经皮管理胆总管结石。
局限性
- Egger检验显示总体并发症存在发表偏倚(p=0.049)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To perform a systematic review and meta-analysis to determine the success and complication rate of percutaneous transhepatic fluoroscopy-guided management (PTFM) for the removal of common bile duct stones (CBDS).
METHODS: A comprehensive literature search of multiple databases was conducted to identify original articles published between January 2010 and June 2022, reporting the success rate of PTFM for the removal of CBDS. A random-effect model was used to summarize the pooled rates of success and complications with 95% confidence intervals (CIs).
RESULTS: Eighteen studies involving 2554 patients met the inclusion criteria and were included in the meta-analysis. Failed or infeasible endoscopic management was the most common indication of PTFM. The meta-analytic summary estimates of PTFM for the removal of CBDS were as follows: rate of overall stone clearance 97.1% (95% CI, 95.7-98.5%); stone clearance at first attempt 80.5% (95% CI, 72.3-88.6%); overall complications 13.8% (95% CI, 9.7-18.0%); major complications 2.8% (95% CI, 1.4-4.2%); and minor complications 9.3% (95% CI, 5.7-12.8%). Egger's tests showed the presence of publication bias with respect to the overall complications (p = 0.049). Transcholecystic management of CBDS had an 88.5% pooled rate for overall stone clearance (95% CI, 81.2-95.7%), with a 23.0% rate for complications (95% CI, 5.7-40.4%).
CONCLUSION: The systematic review and meta-analysis answer the questions of the overall stone clearance, clearance at first attempt, and complication rate of PTFM by summarizing the available literature. Percutaneous management could be considered in cases with failed or infeasible endoscopic management of CBDS.
CLINICAL RELEVANCE STATEMENT: This meta-analysis highlights the excellent stone clearance rate achieved through percutaneous transhepatic fluoroscopy-guided removal of common bile duct stones, potentially influencing clinical decision-making when endoscopic treatment is not feasible.
KEY POINTS: • Percutaneous transhepatic fluoroscopy-guided management of common bile duct stones had a pooled rate of 97.1% for overall stone clearance and 80.5% for clearance at the first attempt. • Percutaneous transhepatic management of common bile duct stones had an overall complication rate of 13.8%, including a major complication rate of 2.8%. • Percutaneous transcholecystic management of common bile duct stones had an overall stone clearance rate of 88.5% and a complication rate of 23.0%.
引用
- Yoon, Jeon, Moon, et al. Effectiveness and complication rates of percutaneous transhepatic fluoroscopy-guided management of common bile duct stones: a single-arm meta-analysis. Eur Radiol. 2023. PMID: 37326663. doi:10.1007/s00330-023-09846-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。